Researchers from the University of Colorado Cancer Center have solved a cellular mystery that may lead to better therapies for colorectal and other types of cancer.

The FDA has approved Tevimbra with chemotherapy for the first-line treatment of unresectable or metastatic ESCC whose tumors express PD-L1.